CIS BIOPHARMA AG

We pioneer precision cancer therapies targeting tumor cells. Our next-gen antibody-drug conjugates and radiopharmaceuticals aim to improve cancer patients' lives globally. We harness antibodies and nanobodies, advancing programs from discovery to clinical validation. The targeted antigens Our targeted antigens span various cancer types. Therefore, our programs comprise attractive market potential for acquisition by pharma upon clinical validation.
We leverage our chemistry expertise to optimize linker/drug configurations to enhance therapeutic index. Our linker platform expertise and bioconjugation infrastructure enables co-development programs, monetizing industry partnerships.